Johnson & Johnson and the governor of Puerto Rico jointly announced an expansion of four existing plants that will add 308 jobs. The company based in New Brunswick, New Jersey will be investing up to $225 million to add capacity the plants in Gurabo, Manati, and San Lorenzo.
Threshold Pharmaceuticals Inc. has reported positive early-stage data for its drug TH-302 as a treatment for glioblastoma, the most aggressive type of brain cancer. The company said that so far, there are no side effects that limit dosing of the drug.
EMD Millipore and the Institute of Bioprocess Engineering and Pharmaceutical Technology, Mittelhessen University of Applied Sciences announced a collaboration to develop optimized cell culture and harvesting processes for bioreactor-based stem cell cultures
Catalyst Pharmaceutical Partners Inc. has been advised by the Department of Veterans Affairs Cooperative Studies Program that the availability of top-line results from Catalyst's vigabatrin Phase 2b trial for cocaine addiction will be delayed.
Biotech company Pharming Group NV announced that it has completed the clinical phase of the Phase 3 clinical study evaluating the investigational drug Ruconest for the treatment of acute attacks of angioedema in patients with hereditary angioedema.
Achillion Pharmaceuticals Inc. announced positive proof-of-concept results for ACH-3102, a pan-genotypic NS5A inhibitor being developed for the treatment of chronic hepatitis C viral infections. Achillion has initiated a Phase 2 clinical trial evaluating ACH-3102 in combination with ribavirin for the treatment of patients with chronic GT 1b HCV.
WorldCare Clinical LLC has announced its Endpoint Assessment Committee services for blinded independent central review of clinical trial data.
BD Diagnostics announced the release of a research use-only molecular test designed to rapidly detect antibiotic resistance genes found in the superbug known as carbapenem-resistant Enterobacteriaceae. These deadly organisms are resistant to nearly all antibiotics.
Berthold Technologies has released the Apollo 11, a dedicated absorbance reader. The instrument has continuously optimized optics as well as a modern LED light source. The optics and mechanical design, combined with the integrated auto-check function, guarantees accuracy.
Apricus Biosciences Inc. will ask Canadian regulators to approve its antifungal drug MycoVa in late 2013. MycoVa is designed to treat onychomycosis, a persistent foot fungus infection that can cause pain as well as thickened and discolored toenails.
Medical device maker Stryker Corp. has named Kevin Lobo, the president of its orthopedics business, as its new president and CEO, effective immediately. Lobo has been with the company since April 2011. He previously held a variety of positions with Johnson & Johnson.
ImmuPharma plc, a specialist drug discovery and development company, announced that its cancer program IPP-204106 has begun further clinical trials with the next generation of polyplexed Nucant. The first patients have started dosing in this Phase 1/2 clinical trial.
Researchers investigating a known gene risk factor for Alzheimer’s disease discovered it is associated with lower levels of beta amyloid—a brain protein involved in Alzheimer’s—in cognitively healthy older people, suggesting another mechanism may be involved.
The older we get, the weaker our immune systems tend to become, leaving us vulnerable to infectious diseases and cancer and eroding our ability to benefit from vaccination. Now, scientists have found that blocking the action of a protein whose levels in our immune cells rise with age can restore those cells’ response to a vaccine.
Abbott Laboratories Inc. said the Food and Drug Administration approved its drug Humira as a treatment for ulcerative colitis in adults. The FDA approved Humira as a treatment for moderate to severe ulcerative colitis when other medicines have not worked.